BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center for RNA Biomedicine - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Center for RNA Biomedicine
X-ORIGINAL-URL:https://rna.umich.edu
X-WR-CALDESC:Events for Center for RNA Biomedicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Detroit
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20230306T160000
DTEND;TZID=America/Detroit:20230306T160000
DTSTAMP:20260512T011105
CREATED:20221202T145321Z
LAST-MODIFIED:20230228T162213Z
UID:10717-1678118400-1678118400@rna.umich.edu
SUMMARY:RNA Innovation Seminar: Lori Isom\, Chair\, Department of Pharmacology
DESCRIPTION:“Dancing to a Different Tune: TANGO Provides Hope for Dravet Syndrome”\nLori Isom\, Ph.D.\nChair\, Department of Pharmacology\nMaurice H. Seevers Collegiate Professor of Pharmacology\nProfessor of Molecular and Integrative Physiology\nProfessor of Neurology\, University of Michigan Medical School\nIn-person: BSRB\, ABC seminar rooms / zoom link \nAbstract: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by high seizure frequency and severity\, intellectual disability\, and a high risk of sudden unexpected death in epilepsy (SUDEP). Most DS patients carry de novo variants in SCN1A leading to haploinsufficiency of the voltage-gated sodium channel a subunit Nav1.1. Scn1a +/-  DS mouse models recapitulate many patient phenotypes\, including severe seizures and SUDEP. DS mice have reduced excitability of parvalbumin-positive (PV+) fast-spiking interneurons\, leading to disinhibition. Targeted Augmentation of Nuclear Gene Output (TANGO) was developed by our collaborators at Stoke Therapeutics to increase protein expression in diseases of haploinsufficiency using antisense oligonucleotide (ASO) technology. TANGO targets naturally occurring\, non-productive alternative splicing events to reduce non-productive mRNA and increase productive mRNA and protein of the target gene by upregulating the wild-type allele. This approach has provided a unique opportunity to develop novel therapeutics to treat DS. We showed previously that a single\, intracerebroventricular (ICV) dose at postnatal day (P)2 of the ASO STK-001\, generated using TANGO technology to prevent inclusion of a nonsense-mediated decay or poison exon in Scn1a\, exon 20N\, increased productive Scn1a transcript and Nav1.1 expression and reduced the incidence of electrographic seizures and SUDEP in a mouse model of DS (SCIENCE TRANSLATIONAL MEDICINE\, 2020\, Vol 12\, Issue 558\, DOI: 10.1126/scitranslmed.aaz6100). Interestingly\, de novo variants in SCN1A exon 20N were shown by others to increase its inclusion\, resulting in haploinsufficiency and DS pathology in patients and in a mouse model. Our preclinical work led to a series of on-going clinical trials for STK-001. Here\, we investigated the mechanism of a surrogate ASO that also targets exon 20N\, ST-1001\, in DS mouse brain. We tested the effects of a single ICV injection of ST-1001 at P2 on the subsequent electrophysiological properties of cortical pyramidal and PV+ fast-spiking interneurons in Scn1a +/- DS and Scn1a +/+ wild-type littermate control mice at P21-25. We show that\, in untreated DS mice\, intrinsic action potential (AP) firing properties of cortical pyramidal neurons were unchanged compared to controls while AP firing properties of PV+ interneurons showed depolarization block. In addition\, sodium current density was reduced in DS PV+ interneurons. The frequency\, but not amplitude\, of inhibitory post-synaptic currents recorded in DS cortical pyramidal neurons was also reduced\, suggesting reduced GABA release from interneurons. Single-dose ST-1001 ASO administration restored excitability and sodium current density in PV+ DS interneurons as well as restored GABAergic signaling to cortical pyramidal neurons. This new work provides key mechanisms for further development of precision medicine approaches to treat patients with DS and related developmental and epileptic encephalopathies. Our next experimental plan will include testing ST-1001 in a newly developed CRISPR transgenic rabbit model of DS as well as in DS patient-derived induced pluripotent stem cell neurons.
URL:https://rna.umich.edu/events/lori-isom/
LOCATION:MI
END:VEVENT
END:VCALENDAR